Prosecution Insights
Last updated: November 18, 2026
Application No. 18/852,244

COMPOSITIONS AND METHODS COMPRISING PLANTS WITH MODIFIED ORGAN SIZE AND/OR PROTEIN COMPOSITION

Non-Final OA §102§112
Filed
Sep 27, 2024
Priority
Apr 01, 2022 — provisional 63/326,608 +1 more
Examiner
CHATTERJEE, JAYANTA
Art Unit
1662
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
BENSON HILL, INC.
OA Round
1 (Non-Final)
44%
Grant Probability
Moderate
1-2
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 44% of resolved cases
44%
Career Allowance Rate
11 granted / 25 resolved
-16.0% vs TC avg
Strong +70% interview lift
Without
With
+70.1%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
59 currently pending
Career history
86
Total Applications
across all art units

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of Group I in the reply filed on 6/30/2026 is acknowledged. The requirement is deemed proper and is made FINAL. Claims Status Claims 1-2, 4, 7, 9, 11, 14-15, 20, 24-27, 31, 35, 37, 54, 59, 62, 65 and 67 are pending. Claims 26-27, 31, 35, 37, 59, 62, 65, and 67 are withdrawn from examination as being part of non-elected groups. Claims 1-2, 4, 7, 9, 11, 14-15, 20, 24 and 54 are being examined. Specification The disclosure is objected to because of the following informalities: Instant specification describes SEQ ID NOs: 1-2 as “Full-length coding sequence of Glycine max BIG SEEDS 1 gene (GmBS1, Glyma.10G244400)” and “Full-length coding sequence of Glycine max BIG SEEDS 2 gene (GmBS2, Glyma. 20G 150000), respectively (spec, p.93, Table 1). However, the sequences are genomic DNA sequences of the GmBS1 and GmBS2 genes and not only of the “coding sequence” of the respective genes. Appropriate correction is required. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 2 and 7 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 2 recites, “… comprising increased seed size, increased biomass, increased yield, and/or increased content of protein, white flake protein, and/or amino acid compared to a control plant or plant part. It is not clear to the Examiner if the claim requires- “increased content of protein, white flake protein, amino acid” and/or “increased seed size, increased biomass, increased yield”; OR (“increased seed size, increased biomass, increased yield”) and/or (“increased content of protein, white flake protein”) and/or (“amino acid”). Claim 7 recites , “… (A) wherein said plant or plant part comprises a BS1 gene and a BS2 gene, and wherein the mutation is located in…” and “(B) wherein the mutation or the modification of the DNA methylation sites is located in a BS gene or homolog thereof: (i) …”. There is no conjunction between (B)(iii) and (B)(iv). It appears that the “or”, as in between (A)(vi) and (A)(vii), is missing, making it unclear whether only one of (B)(i)-(iv) is required, or some combination. It is suggested to include a conjunction (e.g., “or”) in between (B)(iii) and (B)(iv). Claim Rejections - 35 USC § 102(a)(1) In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1-2, 4, 7, 9, 11, 14-15, 20, 24 and 54 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Ge et al. (US 20160201076Al) in evidence of Huber et al. (Protein Abundance Control by Non-coding Antisense Transcription, 2016, Cell Reports, 15:2625–2636) and Schmutz et al. (Genome Sequence of the Palaeopolyploid Soybean, 2010, Nature, 463.7278. Published online on 02/11/2009). Ge et al. describes a population of legume plants including soybean plants with enlarged or increased leaves, pods and seeds (Fig. 19, p.3, para 0029, line 1-7; p.2, para 0018, line 6-7; para 0019, line 23) (as recited in claim 54) produced by methods to increase plant seed yield and/or seed size through reduced expression of a BS1 (BIG SEEDS1) gene (abstract) (as recited in claims 1-2, 20 and 24) using antisense, RNAi constructs, or a mutation of the BS1 gene (p.1, para 0005, last 3 lines). An ordinarily skilled artisan would acknowledge that reduced expression by using antisense RNA (or RNAi) leads to reduced activity of the gene and, thus, leading to reduction in the protein level encoded by the gene, which, in turn, leads to reduced activity of the protein, as recited in claim 4 (Huber et al.; highlights; abstract). Ge et al. also describes a BS1 gene, as described by the Applicant (spec, p.93, Table 1), in a soybean plant, which is a legume (as recited in claim 20), encoding a protein having at least 80% sequence identity to instant SEQ ID NO: 3, as recited in claim 7, as shown below. RESULT 1 US-14-861-980-162 Sequence 162, US/14861980 Publication No. US20160201076A1 GENERAL INFORMATION APPLICANT: The Samuel Roberts Noble Foundation, Inc. TITLE OF INVENTION: Manipulating BS1 for Plant Seed Yield FILE REFERENCE: NBLE:090US CURRENT APPLICATION NUMBER: US/14/861,980 CURRENT FILING DATE: 2015-09-22 PRIOR APPLICATION NUMBER: 62/055,498 PRIOR FILING DATE: 2014-09-25 NUMBER OF SEQ ID NOS: 172 SEQ ID NO 162 LENGTH: 346 TYPE: PRT ORGANISM: Glycine max Query Match 100.0%; Score 1808; Length 346; Best Local Similarity 100.0%; Matches 346; Conservative 0; Mismatches 0; Indels 0; Gaps 0; Qy 1 MNGGATTATFRSILDKPLNQLTEDDISQLTREDCRRFLKEKGMRRPSWNKSQAIQQVISL 60 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 1 MNGGATTATFRSILDKPLNQLTEDDISQLTREDCRRFLKEKGMRRPSWNKSQAIQQVISL 60 Qy 61 KALLEPSDDDTPPPPPPAMHHRSHAQPQPQVNLSEPPPPPPKAPPPEEPAFHAAEDIQKS 120 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 61 KALLEPSDDDTPPPPPPAMHHRSHAQPQPQVNLSEPPPPPPKAPPPEEPAFHAAEDIQKS 120 Qy 121 ASSGEKPTETNDTNTNVASPKGCATSGSFGQMTIFYCGKVNVYDRVSPDKARAIMQLATS 180 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 121 ASSGEKPTETNDTNTNVASPKGCATSGSFGQMTIFYCGKVNVYDRVSPDKARAIMQLATS 180 Qy 181 PVQLTQDDPLNGNAAVWTSPCHLPMDKDVLVPVDTTILQVAQADKMVEYPLQYREKGSIA 240 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 181 PVQLTQDDPLNGNAAVWTSPCHLPMDKDVLVPVDTTILQVAQADKMVEYPLQYREKGSIA 240 Qy 241 RDADVEGQEHRKVSLQRYLEKRKDRGRLKGKKLTGITSSNFEMYLNLPVKVHSSNGNSSR 300 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 241 RDADVEGQEHRKVSLQRYLEKRKDRGRLKGKKLTGITSSNFEMYLNLPVKVHSSNGNSSR 300 Qy 301 SSTSSPPQPRLPLVSSGSDQLKVALPIDLNDKVSLQMFKNAKIQTR 346 |||||||||||||||||||||||||||||||||||||||||||||| Db 301 SSTSSPPQPRLPLVSSGSDQLKVALPIDLNDKVSLQMFKNAKIQTR 346 Ge et al. describes generating a BS1 mutant plants (bs1-1) which has a deletion mutation in the first exon (as recited in claim 9) at 398 bp downstream from the translation initiation codon (p.13, para 0145, last 3 lines). The mutation in the GmBS1 gene can be heterozygous (reads on to “one allele”) or homozygous (reads on to “two alleles”), as described by Ge et al. (p.12, para 0133, line 1) and as recited in claim 7. Ge et al. teaches a homozygous bs1-1 mutant (soybean) plant (p.12, para 0133, line 1) while retaining the other native BIG SEEDS alleles including BS2 (as recited in claim 11) which also help partially retaining the BIG SEEDS activity. It is prudent to mention here that there is more than 90% sequence identity between GmBS1 (SEQ ID NO: 3) and GmBS2 (SEQ ID NO: 4) proteins. The GmBS1 genomic DNA sequence (Glyma. 10G244400) is having 100% sequence identity to instant SEQ ID NO: 1 and comprises a 8 bp deletion of the sequence “GGAACCTT” of nucleotides 389 through 396 of instant SEQ ID NO: 1 (data not shown), as recited in claim 11. The deletion of 8 nucleotide in SEQ ID NO: 1 result in instant SEQ ID NO: 12 (spec, p.93, Table 1). Thus, the GmBS1 gene has a sequence comprising (as recited in claim 11) instant SEQ ID NO: 12 along with 8 extra nucleotide long sequence. It is noted here that the Glyma.10G244400 gene encoding a GmBS1 protein, as described by Ge et al., is also published by Phytozome website citing several references including Schmutz et al. (Genome Sequence of the Palaeopolyploid Soybean, 2010, Nature, 463.7278. Published online on 02/11/2009). Claims 14-15 directly or indirectly depend from claim 4, more precisely part (ii) of claim 4, which is optional in claim 4. Therefore, the DNA methylation modification pattern, as recited in claim 14, is optional. Thus, claims 14-15 can be included in this rejection. Conclusion No claim is allowed. Communication Any inquiry concerning this communication or earlier communications from the examiner should be directed to JAY CHATTERJEE whose telephone number is (703)756-1329. The examiner can normally be reached (Mon - Fri) 8.30 am to 5.30 pm.. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Bratislav Stankovic can be reached at (571) 270-0305. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. J.C. /Jay Chatterjee/ Examiner, Art Unit 1662 /BRATISLAV STANKOVIC/ Supervisory Patent Examiner, Art Units 1661 & 1662
Read full office action

Prosecution Timeline

Sep 27, 2024
Application Filed
Sep 08, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12703870
REGULATION OF ROOT DEVELOPMENT
2y 2m to grant Granted Aug 11, 2026
Patent 12662514
METHODS TO BLOCK APHID TRANSMISSION OF POLEROVIRUSES AND TO DEVELOP VIRUS MANAGEMENT TOOLS
3y 6m to grant Granted Jun 23, 2026
Patent 12649926
USE OF MfERF026 GENE REGULATION IN GROWTH, DEVELOPMENT, AND STRESS TOLERANCE OF MEDICAGO SATIVA
2y 1m to grant Granted Jun 09, 2026
Patent 12642203
TOMATO PLANTS RESISTANT TO TOBRFV, TMV, TOMV AND TOMMV AND CORRESPONDING RESISTANCE GENES
2y 12m to grant Granted Jun 02, 2026
Patent 12635627
PLANTS RESISTANT TO INFECTION BY PEPINO MOSAIC VIRUS
2y 5m to grant Granted May 26, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
44%
Grant Probability
99%
With Interview (+70.1%)
Low
PTA Risk
Based on 25 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month